January 2026
Serotonin
What January 2026's 18 new studies found, synthesized from the papers below. All Serotonin research →
The synthesis
Synthesized from 18 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Serotonin, 5-HT, serotonergic, 5-HT2A receptor, then ranked by relevance.
Research in January 2026 focused on the mechanisms and therapeutic applications of serotonergic psychedelics, particularly psilocybin. Studies consistently found that psilocybin can produce rapid and sustained antidepressant effects, potentially through neuroplasticity and 5-HT2A receptor-mediated signaling, though some effects may involve 5-HT2A-independent pathways. A key caveat is that much of the evidence comes from preclinical models and narrative reviews, with limited large-scale human trials.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| 5-Methoxy-N,N-Dimethyltryptamine: Functional Safety Pharmacology and Video-EEG Assessment of a Short-Acting Serotonergic Psychedelic in Beagle Canines. 2026 | preclinical animal study | 11 | Supports | Intranasal 5-MeO-DMT produced dose-dependent behavioral signs of serotonergic agonism but no seizures or epileptiform discharges on EEG. |
| The Use of Psilocybin in the Treatment of Depressive Disorders: A Narrative Review 2026 | narrative review | Supports | Psilocybin-assisted therapy shows high therapeutic efficacy for depression compared to conventional treatments. | |
| Psilocybin-Induced Neuroplasticity and Sustained Antidepressant Effects 2026 | narrative review | Supports | Psilocybin interventions produce rapid and sustained antidepressant effects, with neuroplasticity as a candidate mechanism. | |
| Psychedelics elicit their effects by 5-HT2A receptor-mediated Gi signalling. 2026 | preclinical study | Supports | Psychedelics elicit hallucinogenic effects via 5-HT2A receptor-mediated Gi signaling, and a Gq-biased derivative showed therapeutic effects without hallucinogenic effects in mice. | |
| Design, Synthesis, and Pharmacokinetic Profiling of Fluorinated Reversible N -Alkyl Carbamate Derivatives of Psilocin for Sub-Hallucinogenic Brain Exposure 2026 | preclinical study | Supports | Fluorinated carbamate derivatives of psilocin reduced acute psychoactive effects while maintaining serotonergic activity. | |
| THE PSYCHEDELIC RENAISSANCE: A SYSTEMATIC REVIEW OF PSILOCYBIN AND LSD IN THE TREATMENT OF PSYCHIATRIC DISORDERS 2026 | systematic review | Supports | Psilocybin and LSD show significant therapeutic potential for treatment-resistant depression, end-of-life distress, and substance use disorders. | |
| Psilocin mediates long-term synaptic depression in the prelimbic cortex through 5-HT2A receptor-independent mechanisms 2026 | preclinical study | Mixed | Psilocin induced long-term synaptic depression in the prelimbic cortex via 5-HT2A-independent mechanisms, involving GABAergic and TrkB signaling. | |
| Psilocybin rapidly, but not immediately, reverses reward learning deficits in a durable manner in an inflammatory rat model of depressive symptoms 2026 | preclinical animal study | Supports | Psilocybin reversed reward learning deficits within 24 hours, with effects lasting at least 7 days. | |
| An exploration of the relationships between the effects of psilocybin on behavior, 5-HT 2A receptor occupancy, and neuroplastic effects in mice 2026 | preclinical animal study | Supports | Psilocybin produced dose-dependent 5-HT2A receptor occupancy and neuroplastic changes in the prefrontal cortex, correlating with behavioral effects. | |
| Snapshot IP 1 Detection Following 5-HT 2 A Receptor Stimulation in the Mouse Brain 2026 | preclinical study | Supports | An ex vivo platform showed that psychedelics like DOI and LSD engage 5-HT2A receptor Gq/11 signaling in a dose-dependent manner, correlating with head twitch response. | |
| The utility of 2,5-dimethoxy-4-iodoamphetamine for the study of serotonin 2A and 2C receptors. 2026 | review | Unclear | DOI is a key tool for studying 5-HT2A and 5-HT2C receptors, and its scheduling may hinder research. | |
| Partydrogen im Überblick 2026 | review | Unclear | Party drugs, including psychedelics, modulate mood and perception through serotonergic and other mechanisms. | |
| The effects of psilocybin on time perception in humans: A comparative analysis of subjective and objective measures 2026 | double-blind placebo-controlled study | 24 | Supports | Psilocybin altered time perception, causing subjective time slowing and decreased temporal precision, especially for durations over 2 seconds. |
| Effects of Serotonergic Psychedelics on Synaptic Function and Neuroplasticity 2026 | preclinical study | Supports | Serotonergic psychedelics decreased synaptic vesicle fusion and modulated neurotransmitter release and network activity. | |
| The entactogen MDMA (3,4-methylenedioxymethamphetamine, "Ecstasy") disrupts helping behaviour while reinforcing electrophysiological indicators of potentially associated synaptic plasticity in male Sprague-Dawley rats. 2026 | preclinical animal study | Opposes | MDMA at higher doses suppressed helping behavior in rats, contrary to the hypothesis that it would enhance prosocial behavior. | |
| LSD 5-HT2A receptor occupancy and global functional connectivity effects 2026 | preclinical/imaging study | Supports | LSD shows 5-HT2A receptor occupancy and global functional connectivity effects in humans. | |
| Psychedelics and the quantum brain: a falsifiable hypothesis on Posner molecules and spin-dependent pharmacology. 2026 | theoretical | Unclear | A speculative hypothesis proposes that psychedelics may interface with quantum processes via Posner molecules. | |
| A Randomized Controlled Trial of Psilocybin for the Treatment of Obsessive-Compulsive Disorder 2026 | randomized controlled trial | Supports | Psilocybin is proposed as a novel treatment for OCD, potentially breaking rigid neuronal patterns. |
Intranasal 5-MeO-DMT produced dose-dependent behavioral signs of serotonergic agonism but no seizures or epileptiform discharges on EEG.
preclinical animal study Sample size: 11
Psilocybin-assisted therapy shows high therapeutic efficacy for depression compared to conventional treatments.
narrative review
Psilocybin interventions produce rapid and sustained antidepressant effects, with neuroplasticity as a candidate mechanism.
narrative review
Psychedelics elicit hallucinogenic effects via 5-HT2A receptor-mediated Gi signaling, and a Gq-biased derivative showed therapeutic effects without hallucinogenic effects in mice.
preclinical study
Fluorinated carbamate derivatives of psilocin reduced acute psychoactive effects while maintaining serotonergic activity.
preclinical study
Psilocybin and LSD show significant therapeutic potential for treatment-resistant depression, end-of-life distress, and substance use disorders.
systematic review
Psilocin induced long-term synaptic depression in the prelimbic cortex via 5-HT2A-independent mechanisms, involving GABAergic and TrkB signaling.
preclinical study
Psilocybin reversed reward learning deficits within 24 hours, with effects lasting at least 7 days.
preclinical animal study
Psilocybin produced dose-dependent 5-HT2A receptor occupancy and neuroplastic changes in the prefrontal cortex, correlating with behavioral effects.
preclinical animal study
An ex vivo platform showed that psychedelics like DOI and LSD engage 5-HT2A receptor Gq/11 signaling in a dose-dependent manner, correlating with head twitch response.
preclinical study
DOI is a key tool for studying 5-HT2A and 5-HT2C receptors, and its scheduling may hinder research.
review
Party drugs, including psychedelics, modulate mood and perception through serotonergic and other mechanisms.
review
Psilocybin altered time perception, causing subjective time slowing and decreased temporal precision, especially for durations over 2 seconds.
double-blind placebo-controlled study Sample size: 24
Serotonergic psychedelics decreased synaptic vesicle fusion and modulated neurotransmitter release and network activity.
preclinical study
MDMA at higher doses suppressed helping behavior in rats, contrary to the hypothesis that it would enhance prosocial behavior.
preclinical animal study
LSD shows 5-HT2A receptor occupancy and global functional connectivity effects in humans.
preclinical/imaging study
A speculative hypothesis proposes that psychedelics may interface with quantum processes via Posner molecules.
theoretical
Psilocybin is proposed as a novel treatment for OCD, potentially breaking rigid neuronal patterns.
randomized controlled trial
Points of agreement
- Psilocybin and other serotonergic psychedelics show rapid and sustained antidepressant effects in preclinical and clinical studies.
- 5-HT2A receptor activation is a key mechanism for psychedelic effects, though some effects may involve other pathways.
- Neuroplasticity is a common proposed mechanism for long-term therapeutic benefits.
Conflicts
- Article_id 18860 found psilocin effects independent of 5-HT2A, while others emphasize 5-HT2A agonism as primary.
- Article_id 28508 found MDMA suppressed helping behavior, contrasting with the expectation of enhanced prosocial effects.
Gaps
- Most studies are preclinical or narrative reviews; large-scale human RCTs are limited.
- Durability of effects beyond 6 months is not well studied.
- Specific populations (e.g., adolescents, elderly) and dose-response relationships need more research.
- The role of quantum effects (article_id 27808) is speculative and untested.